One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment
Abstract Background The novel coronavirus is still mutating, and the pandemic continues. Meanwhile, many COVID-19 survivors have residual postinfection clinical manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been shown to be effective in the early stages of COVID-19. Obj...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-07-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-022-02972-3 |
| _version_ | 1811293624442290176 |
|---|---|
| author | Lei Shi You Zheng Zhi Cheng Ningfei Ji Changming Niu Yan Wang Tingrong Huang Ruyou Li Mao Huang Xiaolin Chen Lei Shu Mingjing Wu Kaili Deng Jing Wei Xueli Wang Yang Cao Jiaxin Yan Ganzhu Feng |
| author_facet | Lei Shi You Zheng Zhi Cheng Ningfei Ji Changming Niu Yan Wang Tingrong Huang Ruyou Li Mao Huang Xiaolin Chen Lei Shu Mingjing Wu Kaili Deng Jing Wei Xueli Wang Yang Cao Jiaxin Yan Ganzhu Feng |
| author_sort | Lei Shi |
| collection | DOAJ |
| description | Abstract Background The novel coronavirus is still mutating, and the pandemic continues. Meanwhile, many COVID-19 survivors have residual postinfection clinical manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been shown to be effective in the early stages of COVID-19. Objectives The aim of this study was to investigate long-term safety and efficacy of treatment in patients with severe COVID-19 patients who had received hUC-MSCs therapy. Methods Twenty-five discharged patients who had severe COVID-19 (including the standard treatment group and the standard treatment plus hUC-MSCs group) were enrolled in a 1-year follow-up. The assessment considered adverse effects (including effects on liver and kidney function, coagulation, ECG, tumor marker, and so on), pulmonary function, St George’s Respiratory Questionnaire (SGRQ), postinfection sequelae and serum concentration of Krebs von den Lungen-6 (KL-6), malondialdehyde (MDA), H2S, carnitine, and N-6 long-chain polyunsaturated fatty acids (N-6 LC-PUFAs). Measurements and main results Pulmonary ventilation function had significantly improved at the 1-year follow-up in both the hUC-MSCs group and the control group compared with the 3-month follow-up (P < 0.01). Fatigue (60% [15/25]) remained the most common symptom at the 1-year follow-up. The rate of fatigue relief was significantly reduced in the hUC-MSCs group (25% [2/8]) compared to the control group (76.5% [13/17]) (P = 0.028). The level of KL-6 was significantly lower in the hUC-MSCs group (2585.5 ± 186.5 U/ml) than in the control group (3120.7 ± 158.3 U/ml) (P < 0.001). Compared with the control group, the hUC-MSCs group had a lower level of MDA (9.27 ± 0.54 vs. 9.91 ± 0.72 nmol/ml, P = 0.036). No obvious adverse effects were observed in the hUC-MSCs treatment group at 1 year after discharge. Conclusions Intravenous transplantation of hUC-MSCs was a safe approach in the long term in the treatment of patients with severe COVID-19. In addition, hUC-MSCs had a positive effect on postinfection sequelae in COVID-19 survivors. Trial registration Chinese Clinical Trial Registration; ChiCTR2000031494; Registered 02 April 2020—Retrospectively registered, http://www.medresman.org |
| first_indexed | 2024-04-13T05:04:14Z |
| format | Article |
| id | doaj.art-200f04a39e8d4ae7a9e50d84390df538 |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-04-13T05:04:14Z |
| publishDate | 2022-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-200f04a39e8d4ae7a9e50d84390df5382022-12-22T03:01:14ZengBMCStem Cell Research & Therapy1757-65122022-07-0113111210.1186/s13287-022-02972-3One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatmentLei Shi0You Zheng1Zhi Cheng2Ningfei Ji3Changming Niu4Yan Wang5Tingrong Huang6Ruyou Li7Mao Huang8Xiaolin Chen9Lei Shu10Mingjing Wu11Kaili Deng12Jing Wei13Xueli Wang14Yang Cao15Jiaxin Yan16Ganzhu Feng17Department of Pulmonary and Critical Medicine, the Second Affiliated Hospital of Nanjing Medical UniversityDepartment of Nephrology, Huangshi Hospital of Traditional Chinese MedicineDepartment of Critical Care Medicine, the Second Affiliated Hospital of Nanjing Medical UniversityDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Critical Care Medicine, the Second Affiliated Hospital of Nanjing Medical UniversityJiangsu Cell Tech Medical Research InstituteDepartment of Nephrology, Huangshi Hospital of Traditional Chinese MedicineDepartment of Respiratory Medicine, Huangshi Central HospitalDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical UniversityDepartment of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical UniversityDepartment of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical UniversityDepartment of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical UniversityDepartment of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical UniversityDepartment of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical UniversityDepartment of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical UniversityDepartment of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical UniversityDepartment of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical UniversityDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Nanjing Medical UniversityAbstract Background The novel coronavirus is still mutating, and the pandemic continues. Meanwhile, many COVID-19 survivors have residual postinfection clinical manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been shown to be effective in the early stages of COVID-19. Objectives The aim of this study was to investigate long-term safety and efficacy of treatment in patients with severe COVID-19 patients who had received hUC-MSCs therapy. Methods Twenty-five discharged patients who had severe COVID-19 (including the standard treatment group and the standard treatment plus hUC-MSCs group) were enrolled in a 1-year follow-up. The assessment considered adverse effects (including effects on liver and kidney function, coagulation, ECG, tumor marker, and so on), pulmonary function, St George’s Respiratory Questionnaire (SGRQ), postinfection sequelae and serum concentration of Krebs von den Lungen-6 (KL-6), malondialdehyde (MDA), H2S, carnitine, and N-6 long-chain polyunsaturated fatty acids (N-6 LC-PUFAs). Measurements and main results Pulmonary ventilation function had significantly improved at the 1-year follow-up in both the hUC-MSCs group and the control group compared with the 3-month follow-up (P < 0.01). Fatigue (60% [15/25]) remained the most common symptom at the 1-year follow-up. The rate of fatigue relief was significantly reduced in the hUC-MSCs group (25% [2/8]) compared to the control group (76.5% [13/17]) (P = 0.028). The level of KL-6 was significantly lower in the hUC-MSCs group (2585.5 ± 186.5 U/ml) than in the control group (3120.7 ± 158.3 U/ml) (P < 0.001). Compared with the control group, the hUC-MSCs group had a lower level of MDA (9.27 ± 0.54 vs. 9.91 ± 0.72 nmol/ml, P = 0.036). No obvious adverse effects were observed in the hUC-MSCs treatment group at 1 year after discharge. Conclusions Intravenous transplantation of hUC-MSCs was a safe approach in the long term in the treatment of patients with severe COVID-19. In addition, hUC-MSCs had a positive effect on postinfection sequelae in COVID-19 survivors. Trial registration Chinese Clinical Trial Registration; ChiCTR2000031494; Registered 02 April 2020—Retrospectively registered, http://www.medresman.orghttps://doi.org/10.1186/s13287-022-02972-3Coronavirus disease 2019 (COVID-19)Human umbilical cord mesenchymal stem cells (h-UC-MSCs)1-Year follow-upSequelaeSafety |
| spellingShingle | Lei Shi You Zheng Zhi Cheng Ningfei Ji Changming Niu Yan Wang Tingrong Huang Ruyou Li Mao Huang Xiaolin Chen Lei Shu Mingjing Wu Kaili Deng Jing Wei Xueli Wang Yang Cao Jiaxin Yan Ganzhu Feng One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment Stem Cell Research & Therapy Coronavirus disease 2019 (COVID-19) Human umbilical cord mesenchymal stem cells (h-UC-MSCs) 1-Year follow-up Sequelae Safety |
| title | One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment |
| title_full | One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment |
| title_fullStr | One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment |
| title_full_unstemmed | One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment |
| title_short | One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment |
| title_sort | one year follow up study after patients with severe covid 19 received human umbilical cord mesenchymal stem cells treatment |
| topic | Coronavirus disease 2019 (COVID-19) Human umbilical cord mesenchymal stem cells (h-UC-MSCs) 1-Year follow-up Sequelae Safety |
| url | https://doi.org/10.1186/s13287-022-02972-3 |
| work_keys_str_mv | AT leishi oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT youzheng oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT zhicheng oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT ningfeiji oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT changmingniu oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT yanwang oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT tingronghuang oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT ruyouli oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT maohuang oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT xiaolinchen oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT leishu oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT mingjingwu oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT kailideng oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT jingwei oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT xueliwang oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT yangcao oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT jiaxinyan oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment AT ganzhufeng oneyearfollowupstudyafterpatientswithseverecovid19receivedhumanumbilicalcordmesenchymalstemcellstreatment |